NCT06226883

Who might be able to join this trial:

• You have had signs or symptoms of Crohn's disease (CD) for at least 90 days before the screening visit.
• Your Crohn's disease is considered moderately to severely active, based on a specific scoring system called the CDAI (with a score between 220 and 450), and you have frequent loose stools and/or significant abdominal pain on a daily basis.
• A camera examination of your gut (such as a colonoscopy) shows a certain level of active inflammation, based on a scoring system called the SES-CD (confirm with trial site for exact score details).
• Previous treatments for Crohn's disease have not worked well enough for you, stopped working over time, or caused side effects you could not tolerate — this includes steroids, medications that suppress the immune system (such as azathioprine, 6-mercaptopurine, or methotrexate), or more advanced treatments like biologic medicines or JAK inhibitors.

Who may not be able to join:

• You have been diagnosed with a different type of bowel condition, such as ulcerative colitis, microscopic colitis, ischemic colitis, or radiation colitis, or your symptoms suggest you might have ulcerative colitis.
• Your Crohn's disease only affects certain parts of the digestive tract (such as the mouth, stomach, or the area around the back passage), without involving the large or small intestine.
• You have had a large section of your bowel removed (more than 100 cm), more than 3 bowel surgeries, or have been diagnosed with short bowel syndrome.
• You are currently being fed through a tube or a drip directly into a vein (intravenous nutrition), or are on a liquid-only formula diet.
• You have certain concerns flagged on a neurological (brain and nerve) screening questionnaire (confirm with trial site).
• You have another serious or unstable health condition alongside your Crohn's disease.
• You have previously been treated with a medicine called vedolizumab or any similar type of drug known as an integrin inhibitor.
• You are currently taking part in another clinical trial, or have received an experimental treatment within the last 30 days.
• You have previously been given the study drug (MORF-057), or you are known to be allergic or sensitive to drugs that work in a similar way.
• You are unable to attend the required study visits or follow the study procedures.
• You have a history of a major neurological condition, such as a stroke, multiple sclerosis, a brain tumour, or a disease affecting the nerves or brain.

Important: Always verify eligibility with the trial site directly before applying.